Davide Danovi

Davide Danovi

Auto-generated profile, based on publicly available information

Davide Danovi

Centre for Gene Therapy and Regenerative Medicine, King’s College London, London, United Kingdom

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2009 in Cell Stem Cell
Verified
Journal Article
Closed access
SPSteven M. Pollard
Steven M. Pollard
KYKoichi Yoshikawa
Koichi Yoshikawa
ICIan D. Clarke
Ian D. Clarke
DDDavide Danovi
Davide Danovi
Stefan H. StrickerStefan H. Stricker
Stefan H. Stricker
PDPeter Dirks
Peter Dirks

10 May 2017 in Nature
Verified
Journal Article
Open access
PDF file
HKHelena Kilpinen
Helena Kilpinen
AGAngela Goncalves
Angela Goncalves
ALAndreas Leha
Andreas Leha
VAVackar Afzal
Vackar Afzal
KAKaur Alasoo
Kaur Alasoo
DGDaniel J. Gaffney
Daniel J. Gaffney
Technology utilizing human induced pluripotent stem cells (iPS cells) has enormous potential to provide improved cellular models of human disease. However, variable genetic and phenotypic characterization of many existing iPS cell lines limits their potential use for research and therapy. Here we describe the systematic generation, genotyping and phenotyping of 711 iPS cell lines derived from 301 healthy individuals by the Human Induced Pluripotent Stem Cells Initiative. Our study outlines the major sources of genetic and phenotypic variation in iPS cells and establishes their suitability as models of complex human traits and cancer. Through genome-wide profiling we find that 5–46% of the variation in different iPS cell phenotypes, including differentiation capacity and cellular morphology, arises from differences between individuals. Additionally, we assess the phenotypic consequences of genomic copy-number alterations that are repeatedly observed in iPS cells. In addition, we present a comprehensive map of common regulatory variants affecting the transcriptome of human pluripotent cells.

24 June 2002 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
ECEmanuela Colombo
Emanuela Colombo
JMJean-Christophe Marine
Jean-Christophe Marine
DDDavide Danovi
Davide Danovi
‪‪‪Brunangelo ‪Falini
‪Brunangelo ‪Falini
PPPier Giuseppe Pelicci
Pier Giuseppe Pelicci

16 December 2004 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
CBCarmen Brenner
Carmen Brenner
RDRachel Deplus
Rachel Deplus
Céline MirjoletCéline Mirjolet
Céline Mirjolet
ALAxelle Loriot
Axelle Loriot
EVEmmanuelle Viré
Emmanuelle Viré
FFFrançois Fuks
François Fuks
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

1 August 2002 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
DMDomenico Migliorini
Domenico Migliorini
EDEros Lazzerini Denchi
Eros Lazzerini Denchi
DDDavide Danovi
Davide Danovi
AJAart Jochemsen
Aart Jochemsen
MCManuela Capillo
Manuela Capillo
JMJean-Christophe Marine
Jean-Christophe Marine
We report here the characterization of a mutant mouse line with a specific gene trap event in the Mdm4 locus. Absence of Mdm4 expression results in embryonic lethality (10.5 days postcoitum [dpc]), which was rescued by transferring the Mdm4 mutation into a Trp53-null background. Mutant embryos were characterized by overall growth deficiency, anemia, improper neural tube closure, and dilation of lateral ventricles. In situ analysis demonstrated increased levels of p21CIP1/Waf1 and lower levels of Cyclin E and proliferating cell nuclear antigen expression. Consistent with lack of 5-bromo-2′-deoxyuridine incorporation, these data suggest a block of mutant embryo cells in the G1 phase of the cell cycle. Accordingly, Mdm4-deficient mouse embryonic fibroblasts manifested a greatly reduced proliferative capacity in culture. Moreover, extensive p53-dependent cell death was specifically detected in the developing central nervous system of the Mdm4 mutant embryos. These findings unambiguously assign a critical role for Mdm4 as a negative regulator of p53 and suggest that Mdm4 could contribute to neoplasias retaining wild-type Trp53. Finally, we provide evidence indicating that Mdm4 plays no role on cell proliferation or cell cycle control that is distinct from its ability to modulate p53 function.

1 July 2004 in Molecular and Cellular Biology
Verified
Journal Article
Open access
PDF file
DDDavide Danovi
Davide Danovi
EMErik Meulmeester
Erik Meulmeester
DPDiego Pasini
Diego Pasini
DMDomenico Migliorini
Domenico Migliorini
MCMaria Capra
Maria Capra
JMJean-Christophe Marine
Jean-Christophe Marine
Human tumors are believed to harbor a disabled p53 tumor suppressor pathway, either through direct mutation of the p53 gene or through aberrant expression of proteins acting in the p53 pathway, such as p14ARF or Mdm2. A role for Mdmx (or Mdm4) as a key negative regulator of p53 function in vivo has been established. However, a direct contribution of Mdmx to tumor formation remains to be demonstrated. Here we show that retrovirus-mediated Mdmx overexpression allows primary mouse embryonic fibroblast immortalization and leads to neoplastic transformation in combination with HRasV12. Furthermore, the human Mdmx ortholog, Hdmx, was found to be overexpressed in a significant percentage of various human tumors and amplified in 5% of primary breast tumors, all of which retained wild-type p53. Hdmx was also amplified and highly expressed in MCF-7, a breast cancer cell line harboring wild-type p53, and interfering RNA-mediated reduction of Hdmx markedly inhibited the growth potential of these cells in a p53-dependent manner. Together, these results make Hdmx a new putative drug target for cancer therapy.